Brexit: Insulin Stockpiles are built up

Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Although all parties involved are looking for a positive outcome of the current negotiations, a so called "hard Brexit" - a scenario in which the U.K. leaves the EU without a full agreement - is possible. This will cause problems in many areas. Preparations are being made in order to deal with it.
According the article "UK's biggest insulin manufacturer building up four-month stockpile in case of no-deal Brexit" in the Independent, about 50% of the insulin needed in the U.K to treat diabetic patients is manufactured by the Danish company NovoNordisk. The company now said that they will build up a stockpile until January 2019 to make sure these diabetic patients will get their medications in the event of a no-deal Brexit. The plan is to have a stockpile lasting for four months. Also the French company Sanofi promised to build up an insulin stockpile (for 14 weeks). The U.K. government has asked companies to build up a six-week stockpile of medications against the consequences of hard Brexit.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years